Notícias
From Molecule to Platform: What the Abogen–Novartis Deal Means for mRNA Innovation
As mRNA therapeutics move into new disease areas, the next challenge is turning promising science into scalable, reproducible development process...
Phase 3 Victory for First Individualized mRNA Cancer Vaccine: What Solutions Are Needed for the New Era of mRNA Therapeutics?
On August 19, 2026, monumental news capable of entering the annals of oncology history arrived: Moderna and Merck jointly announced that the Phase ...
Cancer Cell (IF 44.5) | Tumor Cells Resist Immune Checkpoint Therapy via Macrophage Efferocytosis-Mediated Fatty Acid Recycling
Source: Liang Z, Long X, Wong PP, et al. Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid...
From Research to Regulatory Practice: Advancing NAT-Based Mycoplasma Testing for Biologics
Mycoplasma contamination remains one of the most persistent safety concerns throughout biologics manufacturing—from cell banking and viral vector ...
Fast, Accurate, and Reliable Molecular Diagnostic Solutions for Nipah Virus Surveillance
Urgent Alert: Nipah Virus Outbreak in India
A recent Nipah virus (NiV) outbreak in West Bengal, India has triggered emergency public health resp...
Exciting News! Yeasen’s GMP-Grade UltraAAV PEI Transfection Reagent Achieves FDA DMF Registration
Yeasen Biotechnology has officially received confirmation from the U.S. Food and Drug Administration (FDA): our UltraAAV PEI Transfection Reagent–G...
Synthesis of siRNA and the Role of T4 RNA Ligase 2
Small interfering RNA (siRNA) is a powerful tool in molecular biology, widely used for gene silencing through RNA interference (RNAi). These short,...
Yeasen Groundbreaking Milestone in High Temperature Bst DNA Polymerase Evolution for Eliminating False Positive Issues in LAMP Assays
Published in ACS Catalysis
Loop-mediated isothermal amplification (LAMP) is a powerful DNA amplification technique celebrated for its simplicity...
Avanço na tecnologia de mRNA: Yeasen Revela o segredo de baixa toxicidade e alta tradução dos mutantes da RNA polimerase T7
Enzima projetada reduz nocivos dsRNA, abrindo caminho para terapêuticas de mRNA mais seguras Pesquisadores de Yeasen Biotecnologia e sua subsidi...
Sistema de remoção de ácido nucleico integrado para produzir enzimas moleculares de baixo DNA ultra limpeza
A contaminação por ácido nucleico tem sido um obstáculo significativo no avanço das tecnologias de diagnóstico molecular. À medida que métodos de d...
Parabéns! CARRO DE UCELLO Derivado de sangue do Blood Universal Car-T Aprovado pela US FDA Ind!
Ucello Biotechnology Co., Ltd., um parceiro estratégico chave da Biotecnologia Yeasen, desenvolveu de forma independente uma injeção de células T u...
Compartilhando o relatório de validação do kit ELISA de RNA de fita dupla (dsRNA) para promover a padronização da detecção de dsRNA.
Você está procurando uma maneira confiável de detectar dsRNA residual durante a transcrição in vitro de mRNA? Não procure mais do que o Kit ELISA d...